What oncologists need and require from nuclear medicine

被引:6
作者
Pantaleo, M. A. [1 ]
Fanti, S. [2 ]
Nannini, M. [1 ]
Boschi, S. [3 ]
Nanni, C. [2 ]
Maleddu, A. [1 ]
Rubello, D. [4 ]
Biasco, G. [1 ]
机构
[1] Univ Bologna, Inst Hematol & Med Oncol LA Seragnoli, St Orsola Malpighi Hosp, I-40138 Bologna, Italy
[2] Univ Bologna, St Orsola Malpighi Hosp, Nucl Med Serv, I-40138 Bologna, Italy
[3] Univ Bologna, St Orsola Malpighi Hosp, PET Radiopharm Nucl Med Serv, I-40138 Bologna, Italy
[4] IRCCS, Ist Oncol Veneto, S Maria Misericordia Hosp, Dept Nucl Med,PET Ctr, Rovigo, Italy
关键词
F-18-FDG-PET; nuclear medicine; oncology; oncology PET; oncology therapy PET oncology;
D O I
10.1007/s00259-008-0825-y
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
引用
收藏
页码:1761 / 1765
页数:5
相关论文
共 41 条
[1]   Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation [J].
Antonescu, CR ;
Besmer, P ;
Guo, TH ;
Arkun, K ;
Hom, G ;
Koryotowski, B ;
Leversha, MA ;
Jeffrey, PD ;
Desantis, D ;
Singer, S ;
Brennan, MF ;
Maki, RG ;
DeMatteo, RP .
CLINICAL CANCER RESEARCH, 2005, 11 (11) :4182-4190
[2]   Application of PET/CT in the development of novel anticancer drugs [J].
Boss, David S. ;
Olmos, Renato Valdes ;
Sinaasappel, Michiel ;
Beijnen, Jos H. ;
Schellens, Jan H. M. .
ONCOLOGIST, 2008, 13 (01) :25-38
[3]   Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody [J].
Cai, Weibo ;
Chen, Kai ;
He, Lina ;
Cao, Qizhen ;
Koong, Albert ;
Chen, Xiaoyuan .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (06) :850-858
[4]   Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria [J].
Choi, Haesun ;
Charnsangavej, Chuslip ;
Faria, Silvana C. ;
Macapinlac, Homer A. ;
Burgess, Michael A. ;
Patel, Shreyaskumar R. ;
Chen, Lei L. ;
Podoloff, Donald A. ;
Benjamin, Robert S. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1753-1759
[5]   Molecular portraits and the family tree of cancer [J].
Chung, CH ;
Bernard, PS ;
Perou, CM .
NATURE GENETICS, 2002, 32 (Suppl 4) :533-540
[6]   Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J].
Chung, KY ;
Shia, J ;
Kemeny, NE ;
Shah, M ;
Schwartz, GK ;
Tse, A ;
Hamilton, A ;
Pan, D ;
Schrag, D ;
Schwartz, L ;
Klimstra, DS ;
Fridman, D ;
Kelsen, DP ;
Saltz, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :1803-1810
[7]  
Collingridge DR, 2002, CANCER RES, V62, P5912
[8]  
DEMATTEO R, 2007, P AN M AM SOC CLIN, V25, pS18
[9]   Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].
Di Fiore, F. ;
Blanchard, F. ;
Charbonnier, F. ;
Le Pessot, F. ;
Lamy, A. ;
Galais, M. P. ;
Bastit, L. ;
Killian, A. ;
Sesboue, R. ;
Tuech, J. J. ;
Queuniet, A. M. ;
Paillot, B. ;
Sabourin, J. C. ;
Michot, F. ;
Michel, P. ;
Frebourg, T. .
BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169
[10]   Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor [J].
Heinrich, MC ;
Corless, CL ;
Demetri, GD ;
Blanke, CD ;
von Mehren, M ;
Joensuu, H ;
McGreevey, LS ;
Chen, CJ ;
Van den Abbeele, AD ;
Druker, BJ ;
Kiese, B ;
Eisenberg, B ;
Roberts, PJ ;
Singer, S ;
Fletcher, CDM ;
Silberman, S ;
Dimitrijevic, S ;
Fletcher, JA .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4342-4349